---
figid: PMC4440880__3236f1
figtitle: Activation and targeting of prosurvival pathways mediating FLT3 resistance
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC4440880
filename: 3236f1.jpg
figlink: /pmc/articles/PMC4440880/figure/F1/
number: F1
caption: 'Activation and targeting of prosurvival pathways mediating FLT3 resistance.
  (A) The downstream effectors pERK, pAKt, pS6K, and pSTAT are not sufficiently inhibited
  despite FLT3 signaling blockade in sorafenib-resistant FLT3 cell lines harboring
  acquired point mutations in the tyrosine kinase domains. The MEK/ERK pathway likely
  plays a central role in this feedback modulation with smaller contributions from
  the PI3K/AKT and STAT5 pathways. Circulating blasts are dependent on FLT3 signaling
  for activation of the MEK/ERK pathways. Stromal cytokines may activate the MEK/ERK
  pathway in stromal leukemia blasts independent of FLT3-ITD signaling, such as through
  CXCL12/CXCR4 interactions, conferring resistance to the clinically available FLT3
  inhibitors. (B) Concomitant inhibition of CXCR4 (plerixafor), Pi3K (Pi3K inhibitors:
  BKM-120, IPI-145, BYL-719), MEK/ERK (PD0325901, trametinib, MEK-162, E6201), AKT/mTOR
  (mTOR inhibitors: CCI-779, everolimus), NF-κB inhibitors (early clinical trials),
  PiM-kinase inhibitors (early clinical trials), and FLT3 produces a synergistic effect
  in sorafenib-resistant cell lines.'
papertitle: Secondary mutations as mediators of resistance to targeted therapy in
  leukemia.
reftext: Naval Daver, et al. Blood. 2015 May 21;125(21):3236-3245.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.817548
figid_alias: PMC4440880__F1
figtype: Figure
redirect_from: /figures/PMC4440880__F1
ndex: 1ca582c8-df09-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4440880__3236f1.html
  '@type': Dataset
  description: 'Activation and targeting of prosurvival pathways mediating FLT3 resistance.
    (A) The downstream effectors pERK, pAKt, pS6K, and pSTAT are not sufficiently
    inhibited despite FLT3 signaling blockade in sorafenib-resistant FLT3 cell lines
    harboring acquired point mutations in the tyrosine kinase domains. The MEK/ERK
    pathway likely plays a central role in this feedback modulation with smaller contributions
    from the PI3K/AKT and STAT5 pathways. Circulating blasts are dependent on FLT3
    signaling for activation of the MEK/ERK pathways. Stromal cytokines may activate
    the MEK/ERK pathway in stromal leukemia blasts independent of FLT3-ITD signaling,
    such as through CXCL12/CXCR4 interactions, conferring resistance to the clinically
    available FLT3 inhibitors. (B) Concomitant inhibition of CXCR4 (plerixafor), Pi3K
    (Pi3K inhibitors: BKM-120, IPI-145, BYL-719), MEK/ERK (PD0325901, trametinib,
    MEK-162, E6201), AKT/mTOR (mTOR inhibitors: CCI-779, everolimus), NF-κB inhibitors
    (early clinical trials), PiM-kinase inhibitors (early clinical trials), and FLT3
    produces a synergistic effect in sorafenib-resistant cell lines.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - fl
  - ras
  - Ras64B
  - Ras85D
  - Shc
  - Raf
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Dsor1
  - Akt
  - Mtor
  - Tor
  - rl
  - Dif
  - dl
  - Rel
  - lds
  - CXCR4
  - FLT3
  - CXCL12
  - CXCL10
  - CXCL11
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - CXCL8
  - PPBP
  - KRAS
  - HRAS
  - NRAS
  - SHC1
  - SHC2
  - SHC3
  - SHC4
  - ZHX2
  - ARAF
  - BRAF
  - RAF1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - PIM1
  - LONP1
  - MAP2K1
  - MAP2K2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - MAPK3
  - MAPK1
  - NFKB1
  - STAT5A
  - STAT5B
  - PD0325901
  - trametinib
  - Cancer
  - Cardiomyopathy
  - Lung cancer
  - Noonan syndrome
---
